ABSTRAK
INTRODUCTION
Talaromyces (Penicillium) marneffei is a dimorphic fungus that causes a lethal fungal infection known as talaromycosis (penicilliosis) marneffei. Talaromycosis marneffei is endemic especially among human immunodeficiency virus (HIV)-infected patients in Southeast Asia (Vanittanakom et al. 2006; Le et al. meningitis (Supparatpinyo et al. 1994) . In Thailand, the prevalence among HIV infected patients was about 60% (Sirisanthana & Supparatpinyo 1998) . In Vietnam, talaromycosis mean incidence of 4.4% was directly proportionate to the trends of AIDS admissions between 2004 and 2009 (Le et al. 2011 . Talaromycosis in Malaysia has not been extensively studied. A previous study in Malaysia reported that the prevalence of T. marneffei among all fungi cultured from clinical specimens was 14% (Tzar et al. 2013) . In view of a growing HIV incidence in Malaysia, we conducted a larger scale study to determine the epidemiology, clinical features and outcome predictors of Talaromycosis marneffei among HIV-infected patients in Malaysia. This study may give the latest information about the disease burden, trend and clinical features of Talaromycosis marneffei in Malaysia. In addition, clinicians may be able to prognosticate the outcome of the patients based on significant variables found in this study.
MATERIALS AND METHODS
A retrospective, cross sectional study was conducted at Hospital Sungai Buloh (an infectious disease reference centre in Malaysia) from January 2010 to December 2014. By using a formula by Kish (1965) , the calculated sample size was 185 cases. Cultures of specimens, which are positive for T. marneffei were identified from the hospital laboratory (eHIS data statistic) system. Only normally sterile specimens were included in this study 
RESULTS
In 5 years study period (2010 until 2014) , 418 specimens were positive for T. marneffei. However, 227 of 418 specimens were excluded: 188 specimens were duplicates from the same patients; 37 specimens were referred from external healthcare centres; and two cases were excluded on suspicion of contamination. The first of the two presented with a fungating verrucous mass on the dorsum of the third toe, which was diagnosed as squamous cell carcinoma on biopsy. Table 2) . In this study, 82.9% had very low CD4 cell counts. The median CD4 count was 16 cells/L. However, 81.2% were not neutropaenic. The median neutrophil count was 3.34x10 9 /L, which was well within the reference range. Majority of the patients (93.7%) were anaemic, with a mean haemoglobin count of 9.9+2.3 g/dL and more than 60% did not show elevated liver enzymes, with median ALT and ALP counts of 38U/L and 122U/L, respectively (Table 3) .
Antifungal treatment was initiated in 169 (87.6%) of 191 patients. Of 169 patients, 147 (87%) were treated with intravenous amphotericin B deoxycholate as induction therapy followed by itraconazole (119 patients, 70.4%) or fluconazole (28 patients, 16.6%) as maintenance therapy. The standard therapy consisted of intravenous amphotericin B deoxycholate 0.6-0.7 mg/kg/day for 2 weeks, followed by oral itraconazole 400 mg/day for 8 to 10 weeks. After completion of treatment, all patients received oral itraconazole 200 mg/ day as a secondary prophylaxis until the CD4 level is above 200 cells/µL. Other patients received antifungal monotherapy, either with itraconazole (8 patients, 4.7%), fluconazole (3 patients, 1.8%) or amphotericin B (11 patients, 6.5%). These patients were not admitted because of mild symptoms, admission refusal, being transferred to other hospital or patients who passed away during induction therapy with amphotericin B (Table 4) . The outcome was only known for 181 patients. The remaining 10 patients were transferred to other healthcare centres for follow-up care. Of the 181 patients, 148 (81.8%) patients were alive at 8-month assessment after discharge. All-cause mortality rate among the patients was 18.2% (33 out of 181 patients). The causes of death included nosocomial sepsis (8), talaromycosis or severe fungaemia (7), severe sepsis including rhodococcal sepsis (6), disseminated tuberculosis and tuberculous meningitis (3), upper gastrointestinal bleeding (3), meningoencephalitis and encephalitis (3), severe Pneumocystis jiroveci pneumonia (2) and haemophagocytosis (1). The median CD4 cell count at four months to one year after therapy was 169 cells/µL as compared to 16 cells/ µL prior to therapy (Table 4) .
All covariates were analyzed using univariate logistic regression analysis to assess the prediction of outcome. All non-missing covariates and outcomes were assessable in 181 patients (94.7%). Univariate logistic regression analysis showed that median age, diarrhoea, Pneumocystis jiroveci pneumonia (PCP), toxoplasma encephalitis, intravenous drug user (IVDU) and high alkaline phosphatase (ALP) were significant predictors of patient outcome. However, in multivariate logistic regression analysis, only concurrent PCP (adjusted odds ratio [AOR], 9.892; 95% CI, 3.1-31.1; P<0.001), concurrent toxoplasma encephalitis (AOR, 7.509; 95% CI, 1.2-44.0; P=0.025) and IVDU (AOR, 5.462; 95% CI, 1.7-17.1; P=0.004) showed to be significant independent predictors of outcome (Table 5) .
DISCUSSION
Talaromyces marneffei infection in HIV patients was first reported in Malaysia in 1995 (Rokiah et al. 1995) . A previous study in Hospital Kuala Lumpur Malaysia reported seven cases of talaromycosis among 419 HIV/AIDS patients (1.7%) between 1994 and 2001 (Nissapatorn et al. 2003) . Subsequently in 2012, a Male, Malays and Chinese were the most prevalent gender and races who presented with Talaromycosis marneffei in this study. Male is known to be a predominant gender ranging from 70-80% in other studies of talaromycosis (Kawila et al. 2013; Le et al. 2011; Nor-Hayati et al. 2012) . Previous studies in Northern Thailand and Vietnam had shown that cases of talaromycosis among HIV-infected patients were younger (between 28 and 48.5 years) than HIV uninfected patients (between 50 and 64 years) in (Kawila et al. 2013; Le et al. 2011) . Our study among HIV-infected patients showed a wider age spread between 19 and 74 years (mean age 37.15+9.38 years), which is similar to a previous study in Malaysia by Nor-Hayati et.al. (2012) . The reason for this variation is unclear.
Common clinical presentations of Talaromycosis marneffei in this study were loss of weight, followed by fever, cough, skin lesion, lymphadenopathy, hepatomegaly, diarrhoea and splenomegaly. In Vietnam and Thailand, fever is a more common clinical presentation followed by loss of weight, skin lesion, cough and hepatomegaly (Le et al. 2011; Kawila et al 2013) . However, some symptoms like loss of weight and fever are neither specific nor diagnostic for talaromycosis as they could also be associated with late HIV infection. Since all patients in this study were HIV-infected, it is not surprising that most concurrent infections were the usual opportunistic infections seen in AIDS patients. We found oral candidiasis, tuberculosis, (Le et al. 2011 ). HIV-infected talaromycosis patients were more likely to be leukopaenic than non-HIV-infected patients (Li et al 2016; Kawila et al. 2013) . Correspondingly, we found that the median CD4 count was low at 16 cells/µL, which was similar to other studies that ranged from 7 cells/µL to 14 cells/µL (Le et al. 2011; Nor-Hayati et al. 2012; Kawila et al 2013) . Nearly all cases (96.8%) had CD4 counts of less than 100 cells/µL and 82.9% less than 50 cells/µL, which were a little bit higher compared to another study in Thailand (91.7% and 71.2% of cases, respectively) (Chariyalertsak et al. 1997) . Anaemia was seen in 93.7% of patients with a mean haemoglobin level of 9.9+2.3 g/dL (1.3 g/dL-16.4 g/dL). Anaemia is a common manifestation of talaromycosis as being reported elsewhere (Le et al. 2011; Kawila et al 2013) . About 39% of our infected patients had elevated ALT and ALP levels but in general, the median values fell within normal limits (38U/L and 122U/L, respectively). However, a previous study in the same setting showed an elevated median ALP (259U/L) but normal median ALT (48U/L) (Nor-Hayati et al. 2012 ) while a study in Vietnam showed slightly elevated mean ALT level of 60U/L (Le at al. 2011) . Nevertheless, the variations in the liver enzyme levels could not be directly attributed to talaromycosis because there are many factors that could contribute to this such as concurrent viral hepatitis and drugs.
Talaromycosis is frequently reported as a late manifestation of HIV infection (Supparatpinyo et al. 1992; Hung et al. 1998; Le et al. 2011; Kurup et al. 1999; Ranjana et al. 2002) . We found that almost two-thirds (61.3%) of our patients presented with talaromycosis as an HIV presenting illness (newly diagnosed HIV), which is about 2.5 times higher than a study in Vietnam involving 513 patients (Le et al. 2011) . These findings together with median CD4 of 16 cells/µL may support the idea of listing talaromycosis as an HIV/ AIDS-indicator disease in Malaysia just like in Hong Kong and Thailand (Imwidthaya 1994; Wong et al. 1995) . The study in Vietnam reported that predictors of poor outcome of talaromycosis included IVDU, shorter history, absence of fever or skin lesions, higher respiratory rates, higher absolute lymphocyte count and lower platelet count (Le et al. 2011 ). However, we found that only IVDU, concurrent toxoplasma encephalitis and concurrent PCP independently predicted death outcome. These outcome predictors may help clinicians to prognosticate the disease outcome. PCP and toxoplasma encephalitis are AIDS indicator diseases when the CD4 count is less than 200 cells/ µL, while IVDU is an established independent risk factor for death and/ or development of AIDS (Gadpayle et al. 2012 ). Because HIV infection or AIDS is a known risk factor for Talaromycosis marneffei, IVDU is indirectly related to talaromycosis. Since all patients in this study were HIV positive, we tried to explore whether the mode of HIV acquisition has any weight on the outcome of patients infected with Talaromyces marneffei. Apparently, IVDU shows significant association to death but not the other modes of acquisition. The reason for this is unclear. Perhaps patients with IVDU had more severe HIV infection and subsequently more severe talaromycosis, which led to higher rates of death. Further, more detailed studies are needed to elucidate this, possibly even at molecular levels. Absence of fever or presence of skin lesions was not found to be a significant predictor even during univariate analysis. The laboratory characteristics such as neutrophil count, haemoglobin, ALP, ALT and CD4 levels were also not significant predictors of mortality. The mortality rate of talaromycosis in this study was 18.2%, which is a bit lower than 20-29% mortality rates in Vietnam and Thailand (Le at al 2011; Kawila et al. 2013) . Most of our patients who recovered from talaromycosis received the recommended treatment for talaromycosis, which is intravenous amphotericin B as an induction therapy followed by oral itraconazole as a maintenance therapy (Ministry of Health Malaysia 2014). Our study limitations include a relatively small sample size, retrospective study design with some missing data and absence of autopsy evidence to the causes of deaths. However, despite these limitations, this study still provides the latest and largest clinicoepidemiological data and outcome predictors of talaromycosis in Malaysia. In conclusion, Talaromycosis marneffei incidence in Malaysia is rising among HIV infected patients. The most common clinical manifestations are loss of weight, fever and cough. Concurrent IVDU, toxoplasma encephalitis and PCP were significantly associated with mortality.
